Clinical Trials Browser

Anatomic Stage IV Breast Cancer AJCC v8

Triple Negative Breast Neoplasms

Multiple Myeloma, Plasmacytoma

Anus Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Sarcoma, Kaposi, HIV Infections

Leukemia, Myeloid, Acute

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Mycosis Fungoides, Sezary Syndrome

Smoldering Multiple Myeloma, Multiple Myeloma

Uveal Melanoma

Myeloproliferative Disorders, Thrombocytosis

Mesothelioma

Lymphoma, Large B-Cell, Diffuse

Prostatic Neoplasms

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Squamous Intraepithelial Lesions

Squamous Cell Carcinoma of Head and Neck

Breast Neoplasms

Breast Neoplasms

AIDS-related Kaposi sarcoma, Sarcoma, Kaposi, HIV Infections

Liposarcoma, Sarcoma

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Breast Neoplasms, Inflammatory Breast Neoplasms

Clinical Trials

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Observation or Radical Treatment in Patients With Prostate Cancer

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer

18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma

Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer